These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Tsurumaru M Surg Oncol; 2006 Aug; 15(2):107-13. PubMed ID: 17097874 [TBL] [Abstract][Full Text] [Related]
47. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). Pereira BP; Zhou Y; Gupta A; Leong DT; Aung KZ; Ling L; Pho RW; Galindo M; Salto-Tellez M; Stein GS; Cool SM; van Wijnen AJ; Nathan SS J Cell Physiol; 2009 Dec; 221(3):778-88. PubMed ID: 19746444 [TBL] [Abstract][Full Text] [Related]
48. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Zhai S; Senderowicz AM; Sausville EA; Figg WD Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170 [TBL] [Abstract][Full Text] [Related]
49. Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer. Hassan MS; Cwidak N; Johnson C; Däster S; Eppenberger-Castori S; Awasthi N; Li J; Schwarz MA; von Holzen U Front Pharmacol; 2021; 12():746385. PubMed ID: 34621175 [TBL] [Abstract][Full Text] [Related]
50. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]. Song Y; Shen K; Tang PP Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904 [TBL] [Abstract][Full Text] [Related]
51. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Mihara M; Shintani S; Nakashiro K; Hamakawa H Oral Oncol; 2003 Jan; 39(1):49-55. PubMed ID: 12457721 [TBL] [Abstract][Full Text] [Related]
52. Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Richard C; Matthews D; Duivenvoorden W; Yau J; Wright PS; Th'ng JP Clin Cancer Res; 2005 May; 11(9):3523-9. PubMed ID: 15867255 [TBL] [Abstract][Full Text] [Related]
53. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo. Yang W; Shan Z; Zhou X; Peng L; Zhi C; Chai J; Liu H; Yang J; Zhang Z Cancer Biomark; 2018; 23(4):589-601. PubMed ID: 30475755 [TBL] [Abstract][Full Text] [Related]
54. Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. Thompson L; Wang S; Tawfik O; Templeton K; Tancabelic J; Pinson D; Anderson HC; Keighley J; Garimella R J Orthop Res; 2012 May; 30(5):831-44. PubMed ID: 22042758 [TBL] [Abstract][Full Text] [Related]
55. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Senderowicz AM Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481 [TBL] [Abstract][Full Text] [Related]
57. Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines. Ema Y; Igase M; Takeda Y; Yanase T; Umeki S; Hiraoka H; Okuda M; Mizuno T Vet Comp Oncol; 2016 Aug; 14 Suppl 1():95-106. PubMed ID: 25623777 [TBL] [Abstract][Full Text] [Related]
58. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498 [TBL] [Abstract][Full Text] [Related]
59. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887 [TBL] [Abstract][Full Text] [Related]
60. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Li W; Fan J; Bertino JR Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]